IS5389A - 2,3 -Díarýl-pýrazóló [1,5-b]pýridazín afleiður, framleiðsla þeirra og notkun þeirra sem klóoxýgenasa 2 (cox-2) latar - Google Patents

2,3 -Díarýl-pýrazóló [1,5-b]pýridazín afleiður, framleiðsla þeirra og notkun þeirra sem klóoxýgenasa 2 (cox-2) latar

Info

Publication number: IS5389A
Authority: IS; Iceland
Prior art keywords: chlorogenase; pyrazolo; diaryl; cox; inhibitor
Prior art date: 1997-09-05

Application number

IS5389A

Other languages

English (en)

Inventor

Beswick Paul

Baxter Campbell Ian

Mathews Neil

Naylor Alan

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-05

Filing date

2000-02-25

Publication date

2000-02-25

1997-09-05 Priority claimed from GBGB9718792.6A external-priority patent/GB9718792D0/en

1997-12-23 Priority claimed from GBGB9727116.7A external-priority patent/GB9727116D0/en

2000-02-25 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2000-02-25 Publication of IS5389A publication Critical patent/IS5389A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)

IS5389A 1997-09-05 2000-02-25 2,3 -Díarýl-pýrazóló [1,5-b]pýridazín afleiður, framleiðsla þeirra og notkun þeirra sem klóoxýgenasa 2 (cox-2) latar IS5389A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9718792.6A GB9718792D0 (en)	1997-09-05	1997-09-05	Chemical compounds
GBGB9727116.7A GB9727116D0 (en)	1997-12-23	1997-12-23	Chemical compounds
PCT/EP1998/005558 WO1999012930A1 (en)	1997-09-05	1998-09-03	2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors

Publications (1)

Publication Number	Publication Date
IS5389A true IS5389A (is)	2000-02-25

Family

ID=26312181

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5389A IS5389A (is)	1997-09-05	2000-02-25	2,3 -Díarýl-pýrazóló [1,5-b]pýridazín afleiður, framleiðsla þeirra og notkun þeirra sem klóoxýgenasa 2 (cox-2) latar

Country Status (28)

Country	Link
US (4)	US6451794B1 (is)
EP (3)	EP1369421B1 (is)
KR (1)	KR100382619B1 (is)
CN (1)	CN1155600C (is)
AP (1)	AP1354A (is)
AT (3)	ATE245649T1 (is)
AU (1)	AU744997B2 (is)
BG (1)	BG64420B1 (is)
BR (1)	BR9812046A (is)
CA (1)	CA2303152A1 (is)
DE (3)	DE69816651T2 (is)
DK (1)	DK1032575T3 (is)
EA (1)	EA002775B1 (is)
EE (1)	EE04617B1 (is)
ES (3)	ES2256817T3 (is)
HR (1)	HRP20000122B1 (is)
HU (1)	HUP0003644A3 (is)
IL (1)	IL134688A (is)
IS (1)	IS5389A (is)
NO (1)	NO315559B1 (is)
NZ (1)	NZ502985A (is)
PL (1)	PL194557B1 (is)
PT (1)	PT1032575E (is)
SK (1)	SK283922B6 (is)
TR (1)	TR200000595T2 (is)
TW (1)	TW570922B (is)
WO (1)	WO1999012930A1 (is)
YU (1)	YU11900A (is)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100382619B1 (ko)	1997-09-05	2003-05-09	글락소 그룹 리미티드	2,3-디아릴-피라졸로[1,5-ｂ]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(ｃｏｘ-2) 억제제로서의 용도
JP3420751B2 (ja) *	1998-11-03	2003-06-30	グラクソグループリミテッド	選択的ｃｏｘ‐２インヒビターとしてのピラゾロピリジン誘導体
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU2661400A (en)	1999-02-27	2000-09-21	Glaxo Group Limited	Pyrazolopyridines
GB9929039D0 (en) *	1999-12-08	2000-02-02	Glaxo Group Ltd	Medicaments
US7172769B2 (en)	1999-12-08	2007-02-06	Pharmacia Corporation	Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
GB9930358D0 (en)	1999-12-22	2000-02-09	Glaxo Group Ltd	Process for the preparation of chemical compounds
EP1246621A4 (en)	1999-12-23	2004-11-24	Nitromed Inc	NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE
GB0002312D0 (en) *	2000-02-01	2000-03-22	Glaxo Group Ltd	Medicaments
NZ524252A (en)	2000-07-20	2004-03-26	Lauras As	Cox-2 inhibitors for treating HIV and AIDS
PE20020506A1 (es) *	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021494D0 (en) *	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
GB0025449D0 (en) *	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
DE60112609T2 (de)	2000-12-15	2006-01-19	Glaxo Group Ltd., Greenford	Pyrazolopyridine
JP2004515550A (ja)	2000-12-15	2004-05-27	グラクソグループリミテッド	治療用化合物
WO2002072581A2 (en)	2001-03-08	2002-09-19	Smithkline Beecham Corporation	Pyrazolopyriadine derivatives
EP1372643A1 (en)	2001-03-30	2004-01-02	Smithkline Beecham Corporation	Pyrazolopyridines, process for their preparation and use as therapeutic compounds
DE60212949T2 (de)	2001-04-10	2007-01-04	Smithkline Beecham Corp.	Antivirale pyrazolopyridin verbindungen
US6756498B2 (en)	2001-04-27	2004-06-29	Smithkline Beecham Corporation	Process for the preparation of chemical compounds
EP1385847B1 (en)	2001-04-27	2005-06-01	SmithKline Beecham Corporation	Pyrazolo[1,5-a]pyridine derivatives
GB0112810D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112802D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
PL366827A1 (en)	2001-06-21	2005-02-07	Smithkline Beecham Corporation	Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
AR038957A1 (es)	2001-08-15	2005-02-02	Pharmacia Corp	Terapia de combinacion para el tratamiento del cancer
ATE326466T1 (de)	2001-10-05	2006-06-15	Smithkline Beecham Corp	Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
GB0124936D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124932D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
ES2292839T3 (es)	2001-12-11	2008-03-16	Smithkline Beecham Corporation	Derivados de pirazolo-piridina como agentes contra el herpes.
EP1463730B1 (en) *	2001-12-17	2006-04-19	SmithKline Beecham Corporation	Pyrazolopyridazine derivatives
KR100840907B1 (ko) *	2001-12-28	2008-06-24	씨제이제일제당 (주)	사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난바이피리디닐 유도체
KR100686537B1 (ko)	2001-12-28	2007-02-27	씨제이 주식회사	사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
PL212910B1 (pl)	2002-02-12	2012-12-31	Smithkline Beecham Corp	Pochodna nikotynoamidu, srodek farmaceutyczny i zastosowanie pochodnej nikotynoamidu
GB0206200D0 (en) *	2002-03-15	2002-05-01	Glaxo Group Ltd	Pharmaceutical compositions
JP2005535642A (ja)	2002-06-28	2005-11-24	ニトロメッドインコーポレーティッド	オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
US7235560B2 (en)	2002-08-19	2007-06-26	Glaxo Group Limited	Pyrimidine derivative as selective COX-2 inhibitors
UY27939A1 (es)	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
WO2004033454A1 (en)	2002-10-03	2004-04-22	Smithkline Beecham Corporation	Therapeutic compounds based on pyrazolopyridine derivatives
US20040147581A1 (en) *	2002-11-18	2004-07-29	Pharmacia Corporation	Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0227443D0 (en) *	2002-11-25	2002-12-31	Glaxo Group Ltd	Pyrimidine derivatives
ES2214130B1 (es) *	2003-02-13	2005-12-01	Almirall Prodesfarma, S.A.	2-3'-bipiridinas.
ES2213485B1 (es) *	2003-02-13	2005-12-16	Almirall Prodesfarma, S.A.	Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) *	2003-02-13	2005-12-01	Almirall Prodesfarma, S.A.	3-fenilfuran-2-onas.
US20040220155A1 (en) *	2003-03-28	2004-11-04	Pharmacia Corporation	Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
GB0308185D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308186D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308201D0 (en) *	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
WO2004098619A2 (en)	2003-05-07	2004-11-18	Osteologix A/S	Treating cartilage / bone conditions with water-soluble strontium salts
US20050014729A1 (en) *	2003-07-16	2005-01-20	Pharmacia Corporation	Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
GB0318814D0 (en) *	2003-08-11	2003-09-10	Smithkline Beecham Corp	Novel compounds
GB0319037D0 (en) *	2003-08-13	2003-09-17	Glaxo Group Ltd	7-Azaindole Derivatives
US20050119262A1 (en) *	2003-08-21	2005-06-02	Pharmacia Corporation	Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) *	2003-09-03	2005-03-17	Pharmacia Corporation	Method of cox-2 selective inhibitor and nitric oxide-donating agent
GB0402143D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
US20080051416A1 (en) *	2004-10-05	2008-02-28	Smithkline Beecham Corporation	Novel Compounds
JP2008525439A (ja) *	2004-12-23	2008-07-17	ボイジャー・ファーマシューティカル・コーポレーション	アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはｎｍｄａレセプターアゴニスト
EA200801909A1 (ru)	2004-12-23	2009-06-30	Глэксо Груп Лимитед	Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
US20060269579A1 (en) *	2005-05-25	2006-11-30	Musculoskeletal Research Llc	Compositions for treating osteoarthritis
US7767710B2 (en)	2005-05-25	2010-08-03	Calosyn Pharma, Inc.	Method for treating osteoarthritis
GB0512429D0 (en) *	2005-06-17	2005-07-27	Smithkline Beecham Corp	Novel compound
GB0704407D0 (en)	2007-03-07	2007-04-18	Glaxo Group Ltd	Compounds
US7943658B2 (en)	2007-07-23	2011-05-17	Bristol-Myers Squibb Company	Indole indane amide compounds useful as CB2 agonists and method
US20090163440A1 (en) *	2007-09-26	2009-06-25	Waddell David D	Ion-Channel Regulator Compositions and Methods of Using Same
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
GB0813142D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
GB0813144D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
WO2011012622A1 (en)	2009-07-30	2011-02-03	Glaxo Group Limited	Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en)	2009-08-27	2011-03-03	Glaxo Group Limited	Benzoxazine derivatives as glycine transport inhibitors
GB201000685D0 (en)	2010-01-15	2010-03-03	Glaxo Group Ltd	Novel compounds
GB201007789D0 (en)	2010-05-10	2010-06-23	Glaxo Group Ltd	Novel Compound
GB201007791D0 (en)	2010-05-10	2010-06-23	Glaxo Group Ltd	Novel compounds
EP2590953B1 (en)	2010-07-09	2014-10-29	Convergence Pharmaceuticals Limited	Tetrazole compounds as calcium channel blockers
EP2665729B1 (en)	2011-01-19	2015-04-01	Convergence Pharmaceuticals Limited	Piperazine derivatives as cav2.2 calcium channel blockers
GB201122113D0 (en)	2011-12-22	2012-02-01	Convergence Pharmaceuticals	Novel compounds
GB201417497D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
GB201417500D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
GB201417499D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
WO2018049015A1 (en)	2016-09-07	2018-03-15	Trustees Of Tufts College	Combination therapies using immuno-dash inhibitors and pd-1 antagonists
US20240165148A1 (en)	2021-03-15	2024-05-23	Saul Yedgar	Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
CN115611901B (zh) *	2021-07-16	2024-04-30	华南理工大学	一种氮杂䓬类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5002941A (en)	1985-12-12	1991-03-26	Smithkline Beecham Corporation	Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4925849A (en)	1987-06-15	1990-05-15	Fujisawa Pharmaceutical Company, Ltd.	Pharmaceutically useful pyrazolopyridines
US5155114A (en)	1989-01-23	1992-10-13	Fujisawa Pharmaceutical Company, Ltd.	Method of treatment using pyrazolopyridine compound
GB8901423D0 (en)	1989-01-23	1989-03-15	Fujisawa Pharmaceutical Co	Pyrazolopyridine compound and processes for preparation thereof
JPH05503919A (ja)	1989-06-13	1993-06-24	スミスクライン・ビーチャム・コーポレイション	単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
AU622330B2 (en)	1989-06-23	1992-04-02	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IL95031A (en) *	1989-07-18	2007-03-08	Amgen Inc	Method for the production of a human recombinant tumor necrosis factor inhibitor
WO1991019497A1 (en)	1990-06-12	1991-12-26	Smithkline Beecham Corporation	Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
GB9015764D0 (en)	1990-07-18	1990-09-05	Fujisawa Pharmaceutical Co	Pyrazolopyridine compound and processes for preparation thereof
FR2699077B1 (fr) *	1992-12-16	1995-01-13	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US5300478A (en)	1993-01-28	1994-04-05	Zeneca Limited	Substituted fused pyrazolo compounds
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
JP2788677B2 (ja)	1994-01-10	1998-08-20	メルクフロストカナダインコーポレーテツド	Ｃｏｘ−２阻害剤としてのフェニル複素環
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5552422A (en)	1995-01-11	1996-09-03	Merck Frosst Canada, Inc.	Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
KR19980703559A (ko) *	1995-04-04	1998-11-05	그레이엄브레레톤	이미다조［1,2-ａ］피리딘 유도체
EP0833664A1 (en)	1995-06-12	1998-04-08	G.D. SEARLE & CO.	Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations
ES2247604T3 (es)	1995-06-12	2006-03-01	G.D. SEARLE & CO.	Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US5700816A (en)	1995-06-12	1997-12-23	Isakson; Peter C.	Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
GB9513508D0 (en) *	1995-07-03	1995-09-06	Fujisawa Pharmaceutical Co	Quinazoline derivatives
KR100382619B1 (ko) *	1997-09-05	2003-05-09	글락소 그룹 리미티드	2,3-디아릴-피라졸로[1,5-ｂ]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(ｃｏｘ-2) 억제제로서의 용도
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds

1998
- 1998-09-03 KR KR10-2000-7002322A patent/KR100382619B1/ko not_active Expired - Fee Related
- 1998-09-03 AP APAP/P/2000/001753A patent/AP1354A/en active
- 1998-09-03 US US09/508,029 patent/US6451794B1/en not_active Expired - Fee Related
- 1998-09-03 ES ES04025990T patent/ES2256817T3/es not_active Expired - Lifetime
- 1998-09-03 HU HU0003644A patent/HUP0003644A3/hu unknown
- 1998-09-03 AT AT98947502T patent/ATE245649T1/de not_active IP Right Cessation
- 1998-09-03 DE DE69816651T patent/DE69816651T2/de not_active Expired - Lifetime
- 1998-09-03 NZ NZ502985A patent/NZ502985A/en unknown
- 1998-09-03 IL IL13468898A patent/IL134688A/xx not_active IP Right Cessation
- 1998-09-03 PT PT98947502T patent/PT1032575E/pt unknown
- 1998-09-03 EA EA200000188A patent/EA002775B1/ru not_active IP Right Cessation
- 1998-09-03 CN CNB988108763A patent/CN1155600C/zh not_active Expired - Fee Related
- 1998-09-03 ES ES98947502T patent/ES2203985T3/es not_active Expired - Lifetime
- 1998-09-03 EP EP03077298A patent/EP1369421B1/en not_active Expired - Lifetime
- 1998-09-03 ES ES03077298T patent/ES2231757T3/es not_active Expired - Lifetime
- 1998-09-03 SK SK294-2000A patent/SK283922B6/sk unknown
- 1998-09-03 AT AT03077298T patent/ATE281458T1/de not_active IP Right Cessation
- 1998-09-03 AT AT04025990T patent/ATE317845T1/de not_active IP Right Cessation
- 1998-09-03 AU AU94395/98A patent/AU744997B2/en not_active Ceased
- 1998-09-03 EP EP04025990A patent/EP1510519B1/en not_active Expired - Lifetime
- 1998-09-03 DK DK98947502T patent/DK1032575T3/da active
- 1998-09-03 CA CA002303152A patent/CA2303152A1/en not_active Abandoned
- 1998-09-03 BR BR9812046-8A patent/BR9812046A/pt not_active Application Discontinuation
- 1998-09-03 HR HR960321A patent/HRP20000122B1/xx not_active IP Right Cessation
- 1998-09-03 DE DE69827419T patent/DE69827419T2/de not_active Expired - Lifetime
- 1998-09-03 PL PL98339059A patent/PL194557B1/pl unknown
- 1998-09-03 YU YU11900A patent/YU11900A/sh unknown
- 1998-09-03 EE EEP200000113A patent/EE04617B1/xx not_active IP Right Cessation
- 1998-09-03 WO PCT/EP1998/005558 patent/WO1999012930A1/en not_active Ceased
- 1998-09-03 EP EP98947502A patent/EP1032575B1/en not_active Expired - Lifetime
- 1998-09-03 DE DE69833464T patent/DE69833464T2/de not_active Expired - Lifetime
- 1998-09-03 TR TR2000/00595T patent/TR200000595T2/xx unknown
1999
- 1999-02-19 TW TW088102423A patent/TW570922B/zh not_active IP Right Cessation
2000
- 2000-02-25 IS IS5389A patent/IS5389A/is unknown
- 2000-03-03 NO NO20001102A patent/NO315559B1/no unknown
- 2000-03-28 BG BG104279A patent/BG64420B1/bg unknown
2002
- 2002-08-05 US US10/212,513 patent/US6861429B2/en not_active Expired - Fee Related
- 2002-08-05 US US10/212,514 patent/US6831097B2/en not_active Expired - Fee Related
2004
- 2004-10-27 US US10/974,893 patent/US20050113377A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL339059A1 (en)	2000-12-04
EE04617B1 (et)	2006-04-17
NO20001102L (no)	2000-05-03
AU744997B2 (en)	2002-03-07
HUP0003644A3 (en)	2002-11-28
KR20010023669A (ko)	2001-03-26
HRP20000122A2 (en)	2001-02-28
AP2000001753A0 (en)	2000-03-31
ATE245649T1 (de)	2003-08-15
TR200000595T2 (tr)	2000-12-21
HUP0003644A2 (hu)	2001-09-28
US20030040517A1 (en)	2003-02-27
DE69816651D1 (de)	2003-08-28
PL194557B1 (pl)	2007-06-29
DE69827419T2 (de)	2005-10-27
PT1032575E (pt)	2003-11-28
BR9812046A (pt)	2000-09-26
YU11900A (sh)	2002-11-15
EE200000113A (et)	2000-12-15
DE69833464D1 (de)	2006-04-20
CN1155600C (zh)	2004-06-30
ES2231757T3 (es)	2005-05-16
EA200000188A1 (ru)	2000-10-30
ES2256817T3 (es)	2006-07-16
DE69827419D1 (de)	2004-12-09
DE69833464T2 (de)	2006-08-24
EP1032575B1 (en)	2003-07-23
KR100382619B1 (ko)	2003-05-09
US6831097B2 (en)	2004-12-14
NZ502985A (en)	2002-04-26
JP2001515901A (ja)	2001-09-25
EP1510519A1 (en)	2005-03-02
AP1354A (en)	2004-12-29
IL134688A0 (en)	2001-04-30
SK2942000A3 (en)	2001-03-12
CA2303152A1 (en)	1999-03-18
JP3167700B2 (is)	2001-05-21
SK283922B6 (sk)	2004-05-04
US6861429B2 (en)	2005-03-01
HRP20000122B1 (en)	2003-06-30
EP1369421B1 (en)	2004-11-03
ATE317845T1 (de)	2006-03-15
CN1278263A (zh)	2000-12-27
BG104279A (en)	2000-12-29
EP1369421A1 (en)	2003-12-10
ES2203985T3 (es)	2004-04-16
NO315559B1 (no)	2003-09-22
BG64420B1 (bg)	2005-01-31
EP1510519B1 (en)	2006-02-15
TW570922B (en)	2004-01-11
US6451794B1 (en)	2002-09-17
DK1032575T3 (da)	2003-10-20
US20050113377A1 (en)	2005-05-26
WO1999012930A1 (en)	1999-03-18
ATE281458T1 (de)	2004-11-15
NO20001102D0 (no)	2000-03-03
IL134688A (en)	2005-05-17
US20030008872A1 (en)	2003-01-09
AU9439598A (en)	1999-03-29
EP1032575A1 (en)	2000-09-06
DE69816651T2 (de)	2004-04-01
EA002775B1 (ru)	2002-08-29

Publication	Publication Date	Title
IS5389A (is)	2000-02-25	2,3 -Díarýl-pýrazóló [1,5-b]pýridazín afleiður, framleiðsla þeirra og notkun þeirra sem klóoxýgenasa 2 (cox-2) latar
SI1454907T1 (sl)	2009-04-30	Derivati kninazolina in piridopirimidina
HUP9903691A3 (en)	2001-12-28	Pesticidal karbanilide derivatives, preparation and use thereof
HUP0103673A3 (en)	2003-03-28	Substituted phenyl derivatives, their preparation and use
EP1024130A4 (en)	2004-12-15	BIPHENYL-5-ALKANIC ACID DERIVATIVES AND THEIR USE
CZ20011556A3 (cs)	2001-11-14	Pyrazolopyridinové deriváty
HUP9904051A3 (en)	2002-01-28	4-hetaroylpyrazol derivatives, preparation and use thereof as herbicides
IS5353A (is)	2000-01-19	Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
IL129089A0 (en)	2000-02-17	New derivatives from piperidine-keto acid their preparation and use
IL135451A0 (en)	2001-05-20	3-amino-3-arylpropan-1-ol derivatives, their preparation and use
DK1000063T3 (da)	2003-02-24	4-oxo-3,5-dihydro-4H-pyridazin[4,5-b]indol-1-acetamidderivater, fremstilling heraf og terapeutisk anvendelse heraf
IL131645A (en)	2000-12-06	Pyrimido ¬1,2-a¾indole derivatives and their preparation
HUP0004637A3 (en)	2004-07-28	Ketone peroxide derivatives, their preparation and use
AU6120298A (en)	1998-09-22	2-peperazinone-1-acetic acid derivatives and their use
AU2030197A (en)	1997-09-22	2-aminoethyl-benzofuran derivatives, preparation thereof and therapeutical use thereof
HUP0000491A3 (en)	2001-12-28	Herbicidal substituted 4-benzoyl-pyrazole derivatives, preparation and use thereof
IL136919A0 (en)	2001-06-14	Benzo (c) quinolizine derivatives, their preparation and use
DK1192163T3 (da)	2003-12-08	Dithiepino[6,5-b]pyriner, beslægtede præparater og fremgangsmåder
ZA9811642B (en)	1999-06-24	Pyrido 1,2,4-thiadiazine derivatives their preparation and use
GB2324090B (en)	2000-12-27	5,6-O-alkylidene glucono-1(4)-lactones and derivatives thereof,their preparation and use
IL135452A0 (en)	2001-05-20	3-amino-3-arylpropan-1-ol derivatives, their preparation and use
AU6343499A (en)	2000-05-08	Plant sterol derivatives and use thereof
AU6478600A (en)	2001-03-13	New ethylaziridine derivatives and their preparation methods
SI1032575T1 (en)	2003-12-31	2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
HK1028770A (en)	2001-03-02	2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors